Roberto Tascione

Biography

 Tascione, 54 years, has a long experience in the pharmaceutical sector and started his career at Bristol Myers Squibb Italy, before leading the Primary Care and OTC divisions of Schering Plough. From 2009 to 2014 he was CEO of Gilead Italy and on May 2014 he returned to Bristol Myers Squibb as President and Chief Executive Officer Italy. In recent years he led the arrival on the Italian market of some of the most innovative drugs , including Eviplera and Stribild for HIV, Daklinza for HCV and Opdivo in immuno – oncology. Tascione also served on the General Council of Confindustria and was member of Farmindustria Board and the Committee for the Ethical Code.  

Research Interest

HIV, Daklinza for HCV and Opdivo in immuno – oncology